Erica is Vice President & Head of UCB Ventures, a €150 million strategic corporate venture fund which was set up to invest in innovative, longer term and higher risk opportunities beyond UCB’s current focus areas. Erica began her career at UCB in 2010 as VP Strategy & Partnering, NewMedicines (drug discovery through clinical proof of concept), where she developed and led the UCB-Harvard Research Alliance. In 2012, she became a member of an internal strategy team which shaped UCB's Patient Value Strategy that is being implemented today. As Head of Market Access EMEA 2013-2017, Erica was instrumental in developing regional patient access & pricing strategies, and working with affiliates to drive local execution. During her tenure as Head of Market Access, Erica was the Chair of the European Pharmaceutical Association EFPIA Healthcare Systems Working Group.
Prior to UCB, Erica spent 10 years as a top-ranked biotechnology equity analyst for Merrill Lynch in London, where she conducted financial, valuation and commercial analyses for a coverage universe of 24 publicly listed European biotechnology and mid-cap pharmaceutical companies.
Erica attended Brown University (Rhode Island USA) where she received her BA degrees in Biology and in Comparative Literature. Erica travelled to the UK on a Marshall Scholarship and obtained a PhD in Molecular Biology from the University of Edinburgh, and later an MBA from Heriot-Watt University Business School in Edinburgh. She enjoys running, skiing & family holidays, especially spending time with her two daughters, aged 10 and 14 years.